
Triheptanoin
Triheptanoin is a source of heptanoate fatty acids, which can be metabolized without the enzymes of long chain fatty acid oxidation. In clinical trials, patients with long chain fatty acid oxidation disorders (lc-FAODs) treated with triheptanoin are less likely to develop hypoglycemia, cardiomyopathy, rhabdomyolysis, and hepatomegaly. Complications in lc-FAOD patients are reduced from approximately 60% to approximately 10% with the addition of triheptanoin. Triheptanoin was granted FDA approval on 30 June 2020. — DrugBank
- IUPAC 名称
- 2,3-di(heptanoyloxy)propyl heptanoate
- 分子式
- C24H44O6
- 分子量
- 428.6 g/mol
- 精确质量
- 428.31378912 Da
- XLogP3
- 7.3
- 拓扑极性表面积
- 78.9 Ų
- 氢键供体
- 0
- 氢键受体
- 6
- 共价单元
- 1
- 已定义的立体中心
- 0
又称
另有 16 个已报告名称
外部数据库标识符
于 2026-08-31 通过校验和有效的 CAS 匹配从美国国立卫生研究院 (NIH) PubChem 检索。化学性质不能取代本页的监管决定。